Recce Pharmaceuticals - Topical R327G approaching pivotal stages
Recce Pharmaceuticals has made several strides in advancing its topical gel formulation (R327G) of lead anti-infective therapeutic drug candidate...
254 Views
Recce Pharmaceuticals - Taking a closer look at diabetic foot infections
We highlight the opportunity of topical RECCE® 327 (R327) to address diabetic foot infections (DFIs), which is the leading cause of limb morbidity...
280 Views
Recce Pharmaceuticals - Advances on several fronts
Recce Pharmaceuticals has reported several encouraging developments in recent weeks for its lead development compound RECCE® 327 (R327). The...
254 Views
Recce Pharmaceuticals - R&D advance (A$11.18m) extends runway
Recce Pharmaceuticals recently received A$11.18m as an R&D advance credit through an arrangement with Endpoints Capital for the R&D tax...
324 Views
Recce Pharmaceuticals - Supportive advancements on the pipeline
Recce Pharmaceuticals has announced several positive developments in recent weeks relating to its therapeutic programmes, particularly for lead...
286 Views